Sunitinib [14], a multi‐target Type I TKI inhibiting KIT, PDGFRs, VEGFRs, and RET, was approved in 2006 and is used as a second‐line therapy for imatinib‐resistant GIST. This evidence concerns the gene KIT and gastrointestinal stromal tumor.